Suppression of Demyelinating Diseases by Synthetic Copolymers

  • R. Arnon
  • D. Teitelbaum
Part of the NATO ASI Series book series (NSSA, volume 142)


The experimental animal model for human demyelinating diseases used in our studies is experimental allergic encephalomyelitis (EAE). This is an acute neurological autoimmune disease, which can be induced in a variety of species, ranging from rodents to primates, by the injection of central nervous system (CNS) material in complete Freund’s adjuvant. The disease is associated with clinical manifestations, mainly paralysis of the hind legs, which culminate in death, and with the occurrence of histological lesions with perivascular infiltration in the brain. The clinical symptoms appear usually 2–3 weeks after challenge and are preceded by the histological damage (1,2).


Multiple Sclerosis Multiple Sclerosis Patient Experimental Allergic Encephalomyelitis Synthetic Copolymer Chronic Relapse Experimental Allergic Encephalomyelitis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    P. Y. Paterson, Adv. immunol. 5: 131 (1971)CrossRefGoogle Scholar
  2. 2.
    P. Y. Paterson, “Autoimmunity”, N. Talae, ed., Academic Press, New York (1977).Google Scholar
  3. 3.
    E. R. Einstein, D. M. Robertson, J. M. Dicarpio, and W. Moore, J. Neurochem., 9: 353 (1962).CrossRefGoogle Scholar
  4. 4.
    P. R. Carnegie, Biochem. J., 123: 57 (1971).Google Scholar
  5. 5.
    E. H. Eylar, S. Brostoff, G. Hashim, J. Caccam, and P. Burnett, J. Biol. Chenu, 246: 5770 (1971).Google Scholar
  6. 6.
    E. C. Alvord, “EAE: a useful model for multiple sclerosis”, Alan R. Liss, ed., Inc., New York (1984).Google Scholar
  7. 7.
    L. Ortiz-Ortiz and W. O. Weigle, J. Exp. Med., 144: 604 (1976).CrossRefGoogle Scholar
  8. 8.
    C. C. A. Bernard, J. Leydon, and I. R. Mackay, Eur. J. Immunol., 6: 655 (1976).CrossRefGoogle Scholar
  9. 9.
    C. B. Pettinelli and D. E. McFarlin, J. Immunol., 127: 1420 (1981).Google Scholar
  10. 10.
    R. Arnon and D. Teitelbaum, “The suppression of Experimental Allergic Encephalomyelitis and Multiple Sclerosis”, A. N. Davison and M. L. Cuznor, eds., (1980).Google Scholar
  11. 11.
    R. Arnon, Immunol. Rev., 55: 5 (1981).CrossRefGoogle Scholar
  12. 12.
    F. C. Westall, A. B. Robinson, J. Caccam, J. Jackson and E. H. Eylar, Nature, 222: 22 (1974).Google Scholar
  13. 13.
    D. Teitelbaum, A. Meshorer, T. Hirshsfield, R. Arnon, and M. Sela, Eur. J. Immunol., 1: 242 (1971).CrossRefGoogle Scholar
  14. 14.
    D. Teitelbaum, C. Webb, A. Meshorer, R. Arnon, and M. Sela, Eur.J. Immunol., 3: 273 (1973).CrossRefGoogle Scholar
  15. 15.
    C. Webb, D. Teitelbaum, A. Herz, R. Arnon, and M. Sela, Immunochem., 13: 333 (1976).CrossRefGoogle Scholar
  16. 16.
    C. Webb, D. Teitelbaum, R. Arnon, and M. Sela, Eur. J. Immunol., 3: 279 (1973).CrossRefGoogle Scholar
  17. 17.
    Z. Lando, D. Teitelbaum, and R. Arnon, Israel J. Med. Sci., 15: 868 (1979).Google Scholar
  18. 18.
    D. Teitelbaum, C. Webb, M. Bree, A. Meshorer, R. Arnon, and M. Sela, Clin. Immunol. Immunopathol., 3: 256 (1974).CrossRefGoogle Scholar
  19. 19.
    D. Teitelbaum, A. Meshorer, and R. Arnon, Israel J. Med. Sci., 13: 1038 (1977).Google Scholar
  20. 20.
    C. S. Raine, D. H. Synder, M. P. Valsamis, and S. H. Stone, Lab. Invest., 31: 369 (1974).Google Scholar
  21. 21.
    H. M. Wisniewski and A. B. Keith, Ann. Neurol., 1: 144 (1977).CrossRefGoogle Scholar
  22. 22.
    C. S. Raine, U. Traugott, and S. H. Stone, Science, 201: 445 (1978).CrossRefGoogle Scholar
  23. 23.
    A. B. Keith, R. Arnon, D. Teitelbaum, E. A., Caspary, and M. M. Wisniewski, J. Neurol. Sci., 42: 267 (1979).CrossRefGoogle Scholar
  24. 24.
    Z. Lando, D. Teitelbaum, and R. Arnon, J. Immunol., 123: 2156 (1979).Google Scholar
  25. 25.
    C. C. A. Bernard and P. R. Carnegie, J. Immunol., 114: 1537 (1975).Google Scholar
  26. 26.
    P. W. Askenase, B. J. Hayden, and R. K. Gershon, J. Exp. Med., 141: 607 (1975).CrossRefGoogle Scholar
  27. 27.
    M. Duclos, P. Galanaud, O. Devinsky, M. C. Maillot, and J. Dormont, Eur. J. Immunol., 7: 679 (1977).CrossRefGoogle Scholar
  28. 28.
    H. K. Gill and F. Y. Liew, Eur. J. Immunol., 8: 172 (1978).CrossRefGoogle Scholar
  29. 29.
    J. E. Swierkosz and R. H. Swanborg, Immunol., 115: 631 (1975).Google Scholar
  30. 30.
    C. C. A. Bernard, Clin. Exp. Immunol., 29: 100 (1977).Google Scholar
  31. 31.
    Z. Lando, D. Teitelbaum, and R. Arnon, J. Immunol., 126: 1526 (1981).Google Scholar
  32. 32.
    Z. Lando, Y. Doni, D. Teitelbaum, and R. Arnon, J. Immuno1., 127: 1915 (1981).Google Scholar
  33. 33.
    P. Y. Paterson and E. D. Day, Clin. Immunol. Rev., 1: 581 (1981).Google Scholar
  34. 34.
    M. B. Bornstein, “Progress in Neuropathology” Vol. II, M. M. Zimmerman, ed., Grace and Statton, (1973).Google Scholar
  35. 35.
    M. B. Bornstein and C. S. Raine, Neuropathol. and Applied Neurol., 3: 359 (1977).CrossRefGoogle Scholar
  36. 36.
    O. Abramsky, D. Teitelbaum, and R. Arnon, J. Neurol. Sci., 31: 433 (1977).CrossRefGoogle Scholar
  37. 37.
    M. B. Bornstein, A. I. Miller, D. Teitelbaum, R. Arnon, M. Sela, Ann. Neurol., 11: 317 (1982).CrossRefGoogle Scholar

Copyright information

© Plenum Press, New York 1987

Authors and Affiliations

  • R. Arnon
    • 1
  • D. Teitelbaum
    • 1
  1. 1.Department of Chemical ImmunologyWeizmann Institute of ScienceRehovothIsrael

Personalised recommendations